PMV Pharmaceuticals, Inc. (PMVP)

Market Cap	77.62M
Revenue (ttm)	n/a
Net Income (ttm)	-51.47M
Shares Out	51.75M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,573
Open	1.510
Previous Close	1.500
Day's Range	1.460 - 1.510
52-Week Range	1.400 - 3.470
Beta	1.47
Analysts	Strong Buy
Price Target	5.75 (+283.33%)
Earnings Date	Nov 7, 2024

About PMVP

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 25, 2020
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: PMVP
• Website: https://www.pmvpharma.com

Analyst Forecast

According to 4 analysts, the average rating for PMVP stock is "Strong Buy." The 12-month stock price forecast is $5.75, which is an increase of 283.33% from the latest price.

Price Target

$5.75

(283.33% upside)

Analyst Consensus: Strong Buy